Consensus Recommendations for the Diagnosis, Biomarker Testing, and Clinical Management of Advanced or Metastatic Non-small Cell Lung Cancer With Mesenchymal-Epithelial Transition Exon 14 Skipping Mutations in the Middle East, Africa, and Russia

Consensus Recommendations for the Diagnosis, Biomarker Testing, and Clinical Management of Advanced or Metastatic Non-small Cell Lung Cancer With Mesenchymal-Epithelial Transition Exon 14 Skipping Mutations in the Middle East, Africa, and Russia

Mesenchymal-epithelial transition exon 14 (METex14) skipping mutations occur in about 3%-4% of patients with non-small cell lung cancer (NSCLC). This is an aggressive subtype associated with poor prognosis. METex14 skipping is a potentially targetable mutation. Targeted therapy is a promising treatm...

Full description

Saved in:
Bibliographic Details
Published in:Curēus (Palo Alto, CA) Vol. 15; no. 7; p. e41992
Main Authors: Mahrous, Mervat, Omar Jebriel, Abdalla, Allehebi, Ahmed, Shafik, Amr, El Karak, Fadi, Venturini, Filippo, Alhusaini, Hamed, Meergans, Matthias, Ali Nahit Sendur, Mehmet, Ouda, Mohamed, Al-Nassar, Muath, Kilickap, Saadettin, Al Turki, Saeed, Al-Fayea, Turki, Abdel Kader, Yasser
Format: Journal Article
Language:English
Published: United States Cureus Inc 17-07-2023
Cureus
Subjects:
Biomarkers
Biopsy
Cancer therapies
Chemotherapy
Clinical trials
Epidermal growth factor
Immunotherapy
Kinases
Lung cancer
Lymphoma
Medical diagnosis
Metastasis
Mortality
Mutation
Oncology
Response rates
Sarcoma
Middle East
Saudi Arabia
Africa
Russia
lung cancer
met tyrosine kinase inhibitors
targeted therapy
next-generation sequencing
immunotherapy
overall survival
chemotherapy
met exon 14 skipping mutation
liquid biopsy
non-small-cell lung cancer
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Mesenchymal-epithelial transition exon 14 (METex14) skipping mutations occur in about 3%-4% of patients with non-small cell lung cancer (NSCLC). This is an aggressive subtype associated with poor prognosis. METex14 skipping is a potentially targetable mutation. Targeted therapy is a promising treatment modality for patients with advanced/metastatic METex14-mutant NSCLC. Performing systematic molecular testing to detect the driver mutation is essential for initiating targeted therapy. However, there is a lack of guidelines on molecular testing for assessing the eligibility of patients for targeted therapy. Therefore, a multidisciplinary panel consisting of experts from the Middle East, Africa, and Russia convened via a virtual advisory board meeting to provide their insights on various molecular testing techniques for the diagnosis of METex14 skipping mutation, management of patients with targeted therapies, and developing consensus recommendations for improving the processes. The expert panel emphasized performing molecular testing and liquid biopsy before treatment initiation and tissue re-biopsy for patients with failed molecular testing. Liquid biopsy was recommended as complementary to tissue biopsy for disease monitoring and prognosis. Selective MET inhibitors were recommended as the first and subsequent lines of therapy. These consensus recommendations will facilitate the management of METex14 skipping NSCLC in routine practice and warrant optimum outcomes for these patients.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:2168-8184
2168-8184
DOI:10.7759/cureus.41992